Search Result

Results for "

enveloped

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (1) Arenavirus (3) Bacterial (2) CCR (1) Dihydroorotate Dehydrogenase (1) DNA/RNA Synthesis (1) Drug Isomer (1) Endogenous Metabolite (2) Enterovirus (1) Fungal (1) HCV (1) HIV (2) HPV (1) HSV (5) Influenza Virus (10) Isotope-Labeled Compounds (3) Orthopoxvirus (3) Parasite (1) Proton Pump (1) ROR (1) RSV (2) SARS-CoV (10)
By Research Areas:	Infection (28) Inflammation/Immunology (1) Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14904A

Umifenovir hydrochloride Maximum Cited Publications 8 Publications Verification	Influenza Virus SARS-CoV	Infection
Umifenovir hydrochloride is a potent, orally active broad-spectrum antiviral with activity against a number of enveloped and non-enveloped viruses. Umifenovir hydrochloride is used as an anti-influenza virus agent. Umifenovir hydrochloride could effectively inhibit the fusion of virus with host cells . Umifenovir hydrochloride is an efficient inhibitor of SARS-CoV-2 in vitro. Anti-inflammatory activity .

HY-14904

Umifenovir Maximum Cited Publications 8 Publications Verification	SARS-CoV Influenza Virus	Infection
Umifenovir is a potent, orally active broad-spectrum antiviral agent with activity against a number of enveloped and non-enveloped viruses. Umifenovir is used as an anti-influenza virus agent. Umifenovir could effectively inhibit the fusion of virus with host cells . Umifenovir is an efficient inhibitor of SARS-CoV-2 in vitro . Umifenovir shows anti-inflammatory activity .

HY-14904AS

Umifenovir-d6 hydrochloride	Isotope-Labeled Compounds Influenza Virus SARS-CoV	Infection
Umifenovir-d₆ (hydrochloride) is the deuterium labeled Umifenovir hydrochloride. Umifenovir hydrochloride is a potent, orally active broad-spectrum antiviral with activity against a number of enveloped and non-enveloped viruses. Umifenovir hydrochloride is used as an anti-influenza virus agent. Umifenovir hydrochloride could effectively inhibit the fusion of virus with host cells . Umifenovir hydrochloride is an efficient inhibitor of SARS-CoV-2 in vitro. Anti-inflammatory activity .

HY-14904AR

Umifenovir (hydrochloride) (Standard)	Influenza Virus SARS-CoV	Infection
Umifenovir (hydrochloride) (Standard) is the analytical standard of Umifenovir (hydrochloride). This product is intended for research and analytical applications. Umifenovir hydrochloride is a potent, orally active broad-spectrum antiviral with activity against a number of enveloped and non-enveloped viruses. Umifenovir hydrochloride is used as an anti-influenza virus agent. Umifenovir hydrochloride could effectively inhibit the fusion of virus with host cells . Umifenovir hydrochloride is an efficient inhibitor of SARS-CoV-2 in vitro. Anti-inflammatory activity .

HY-14904R

Umifenovir (Standard)	SARS-CoV Influenza Virus	Infection
Umifenovir (Standard) is the analytical standard of Umifenovir. This product is intended for research and analytical applications. Umifenovir is a potent, orally active broad-spectrum antiviral agent with activity against a number of enveloped and non-enveloped viruses. Umifenovir is used as an anti-influenza virus agent. Umifenovir could effectively inhibit the fusion of virus with host cells . Umifenovir is an efficient inhibitor of SARS-CoV-2 in vitro . Umifenovir shows anti-inflammatory activity .

HY-P991484

ADI-65534	Influenza Virus	Infection
ADI-65534 is a human IgG1 monoclonal antibody (mAb) targeting Envelopment polyprotein, M polyprotein. ADI-65534 can be used in Hantavirus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991483

ADI-65533	Influenza Virus	Infection
ADI-65533 is a human IgG1 monoclonal antibody (mAb) targeting Envelopment polyprotein, M polyprotein. ADI-65533 can be used in Hantavirus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991482

ADI-42898	Influenza Virus	Infection
ADI-42898 is a human IgG1 monoclonal antibody (mAb) targeting Envelopment polyprotein, M polyprotein. ADI-42898 binds to the Gn/Gc complex and blocks the cell entry of seven HCPS- and HFRS-associated hantaviruses. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-151267

SARS-CoV-2-IN-25	SARS-CoV	Infection
SARS-CoV-2-IN-25 (Compound CP026) is a potent SARS-CoV-2 spike pseudoparticle transduction inhibitor with an IC₅₀ of 1.6 μM. SARS-CoV-2-IN-25 inhibits enveloped viruses and liposomes .

HY-151267A

SARS-CoV-2-IN-25 disodium	SARS-CoV	Infection
SARS-CoV-2-IN-25 (Compound CP026) disodium is a potent SARS-CoV-2 spike pseudoparticle transduction inhibitor with an IC₅₀ of 1.6 μM. SARS-CoV-2-IN-25 disodium inhibits enveloped viruses and liposomes .

HY-121527

Amylmetacresol	Enterovirus Influenza Virus Bacterial	Infection Neurological Disease
Amylmetacresol is a phenolic compound with topical antibacterial and antiviral activity. Amylmetacresol works by destroying the protein structure of the virus surface or interfering with the function of the virus lipid membrane. Amylmetacresol inhibits the attachment and replication of respiratory viruses such as human Rhinovirus 1a and influenza virus A, without significant effect on viruses such as HRV8. Amylmetacresol is mainly applied topically to the throat to relieve viral sore throats. Amylmetacresol is more active against enveloped viruses than non-enveloped viruses .

HY-B0222

1-Docosanol 1 Publications Verification Behenyl alcohol	HSV	Infection
1-Docosanol (Behenyl alcohol) is a saturated fatty alcohol with reported inhibitory activity against lipid-enveloped viruses, including herpes simplex virus (HSV) .

HY-19874

RFI-641	RSV	Infection
RFI-641 is a selective inhibitor of the respiratory syncytial virus (RSV), with an IC₅₀ of 50 nM. RFI-641 inhibit binding and fusion of enveloped virus via interaction with the viral fusion protein .

HY-156979

RBT-9	SARS-CoV HCV	Infection
RBT-9 prevents progression to severe COVID-19 and organ failure. RBT-9 also has antiviral effects, as demonstrated in several enveloped viruses, including influenza, HCV, dengue, and yellow fever .

HY-123902

Ophiobolin C Zizanin A	CCR HIV	Infection
Ophiobolin C inhibits CCR5 binding to the envelop protein gp120 and CD4, which is responsible for mediating the entry of HIV-1 into cells . Ophiobolin C is also cytotoxic to chronic lymphocytic leukemia cells .

HY-168015

5-Oxo leukotriene B4	Drug Isomer	Infection
5-Oxo leukotriene B4 is a byproduct in the synthesis of 12-oxo LTB4 (HY-130497) with antiviral activity. 5-Oxo leukotriene B4 is promising for research of viral infections caused by human and animal enveloped RNA viruses .

HY-132191

Pradimicin A	Fungal SARS-CoV HIV	Infection
Pradimicin A (PRM-A) is a potent antifungal agent, with an MIC of 4 μg/mL against Candida rugosa. Pradimicin A has antiviral activities against CoV, HIV and other enveloped viruses. Pradimicin A shows aggregation property, and can recognize d-Man in the presence of Ca ²⁺ ion .

HY-B0222S

1-Docosanol-d45	HSV	Infection
1-Docosanol-d₄₅ is the deuterium labeled 1-Docosanol. 1-Docosanol is a saturated fatty alcohol used traditionally as an emollient, emulsifier, and thickener in cosmetics, and nutritional supplement. 1-Docosanol is an inhibitor of lipid-enveloped viruses including herpes simplex.

HY-B0222R

1-Docosanol (Standard)	HSV	Infection
1-Docosanol (Standard) is the analytical standard of 1-Docosanol. This product is intended for research and analytical applications. 1-Docosanol (Behenyl alcohol) is a saturated fatty alcohol with reported inhibitory activity against lipid-enveloped viruses, including herpes simplex virus (HSV) .

HY-14805

Tecovirimat 1 Publications Verification ST-246	Orthopoxvirus Arenavirus	Infection
Tecovirimat (ST-246) is an orally bioavailable and selective compound against orthopoxviruses including vaccinia, monkeypox, camelpox, cowpox, ectromelia (mousepox), smallpox and variola viruses. Tecovirimat is evaluated against vaccinia, cowpox virus, ectromelia virus with EC₅₀ values of 0.01 μM, 0.48 μM and 0.05 μM, respectively. Tecovirimat targets the orthopoxvirus protein VP37 which is necessary for membrane envelopment of intracellular mature virus particles to form enveloped virus. Tecovirimat exerts antiviral activity on the target of the cowpox virus V061 gene, which is homologous to vaccinia virus F13L, encoding a major envelope protein (p37) required for production of extracellular virus .

HY-14805A

Tecovirimat monohydrate 1 Publications Verification ST-246 monohydrate	Orthopoxvirus Arenavirus	Infection
Tecovirimat (ST-246) monohydrate is the monohydrate form of Tecovirimat (HY-14805). Tecovirimat monohydrate is an orally bioavailable and selective compound against orthopoxviruses [including vaccinia, monkeypox, camelpox, cowpox, ectromelia (mousepox), smallpox and variola viruses]. Tecovirimat monohydrate is evaluated against vaccinia, cowpox virus, ectromelia virus with EC₅₀ values of 0.01 μM, 0.48 μM and 0.05 μM, respectively. Tecovirimat monohydrate targets the orthopoxvirus protein VP37 which is necessary for membrane envelopment of intracellular mature virus particles to form enveloped virus. Tecovirimat monohydrate exerts antiviral activity on the target of the cowpox virus V061 gene, which is homologous to vaccinia virus F13L, encoding a major envelope protein (p37) required for production of extracellular virus. Tecovirimat monohydrate could be used in the study for orthopoxvirus-induced diseases .

HY-169220S

RORγ/DHODH-IN-1	ROR Dihydroorotate Dehydrogenase DNA/RNA Synthesis Isotope-Labeled Compounds	Infection
RORγ/DHODH-IN-1 (compound 1404), a deuterium labeled compound, is a dual RORγ and DHODH inhibitor with IC₅₀ values of 9.7 nM and 100 nM, repaectively. RORγ/DHODH-IN-1 blocks the replication of SARS-CoV-2, HCMV, and *non-enveloped* DNA virus (HAdV5)** .

HY-14805S

Tecovirimat-d4 ST-246-d₄	Isotope-Labeled Compounds Orthopoxvirus Arenavirus	Infection
Tecovirimat-d₄ (ST-246-d₄) is a deuterium-labelled Tecovirimat (HY-14805). Tecovirimat is an orally bioavailable and selective compound against orthopoxviruses [including vaccinia, monkeypox, camelpox, cowpox, ectromelia (mousepox), smallpox and variola viruses]. Tecovirimat is evaluated against vaccinia, cowpox virus, ectromelia virus with EC₅₀ values of 0.01 μM, 0.48 μM and 0.05 μM, respectively. Tecovirimat targets the orthopoxvirus protein VP37 which is necessary for membrane envelopment of intracellular mature virus particles to form enveloped virus. Tecovirimat exerts antiviral activity on the target of the cowpox virus V061 gene, which is homologous to vaccinia virus F13L, encoding a major envelope protein (p37) required for production of extracellular virus. Tecovirimat could be used in the study for orthopoxvirus-induced diseases .

HY-129555

Surfactin 5 Publications Verification	Bacterial HSV Antibiotic	Infection
Surfactin is a potent cyclic lipopeptide biosurfactants consists of four isomers (Surfactin A, B, C and D), which mediates flux of mono-and divalent cations, such as calcium, across lipid bilayer membranes. Surfactin can act as an antimicrobial adjuvant with anti-bacterial, anti-fungal, antimycoplasma and hemolytic effects . Surfactin also has antiviral activity against a variety of enveloped viruses .

HY-17421

Tenatoprazole TU-199	Proton Pump	Infection Inflammation/Immunology
Tenatoprazole (TU-199) is an orally active imidazopyridine-based proton pump inhibitor with a prolonged plasma half-life. Tenatoprazole inhibits hog gastric H ⁺/K ⁺-ATPase activity with an IC₅₀ of 6.2 μM. Tenatoprazole blocks the interaction of ubiquitin with the ESCRT-1 factor Tsg101, inhibits production of several enveloped viruses, including EBV .

HY-W019831

Silicon dioxide Silica; Colloidal anhydrous silica	Endogenous Metabolite	Others
Silicon dioxide (Silica) serves as the core of gold-coated silica nanoparticles, featuring a spherical structure enveloped in a layer of gold nanoparticles on its surface. This composition endows them with distinctive chemical and optical properties, rendering them highly desirable for various applications in medicine, batteries, catalysis, sensors, and spectroscopy. The silica component provides a large surface area, a non-porous nature, outstanding charge transport capabilities, and biocompatibility.

HY-162701

Antiviral agent 58	SARS-CoV Influenza Virus RSV HSV	Infection
Antiviral agent 58 (Compound J1) is an orally active antiviral agent with broad-spectrum antiviral activity against enveloped viruses, including influenza A virus (IAV), respiratory syncytial virus (RSV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), human coronavirus OC43 (HCoV-OC43), herpes simplex virus type 1 (HSV-1), and HSV-2 .

HY-P5694

Human α-defensin 5	HPV Parasite	Infection
Human α-defensin 5 is an antiviral peptide. Human α-defensin 5 blocks infection of non-enveloped viruses, including AdV, HPV, and polyomaviruses (IC₅₀: 0.6-1.25 μM for HPV16). Human α-defensin 5 can bind to the viral capsid and blocks escape of the virus from the endosome. Human α-defensin 5 increases HIV binding to the cell surface. Human α-defensin 5 also has parasiticidal activity .

HY-103300

NPE-caged-proton	Endogenous Metabolite	Infection
NPE-caged-proton is a reagent that releases protons under UV light and has the activity of activating the fusion protein GP64 under weak acidic conditions. NPE-caged-proton can promote the binding of enveloped viruses to liposome membranes with acidic phospholipids in an environment of pH 4.0 to 5.5, thereby initiating membrane fusion. The ultraviolet unblocking effect of NPE-caged-proton can lower the environmental pH, thereby triggering the process of viral membrane fusion. When studying the interaction between viruses and cell membranes, NPE-caged-proton provides a valuable tool for revealing the subtle behaviors of viruses in different chemical and biochemical environments .

Cat. No.	Product Name

HY-L073

Anti-Hepatitis C Virus Compound Library	344 compounds
Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle. MCE offers a unique collection of 344 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Anti-Hepatitis C Virus Compound Library

344 compounds

Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.

MCE offers a unique collection of 344 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Cat. No.	Product Name	Target	Research Area

HY-P5694

Human α-defensin 5	HPV Parasite	Infection
Human α-defensin 5 is an antiviral peptide. Human α-defensin 5 blocks infection of non-enveloped viruses, including AdV, HPV, and polyomaviruses (IC₅₀: 0.6-1.25 μM for HPV16). Human α-defensin 5 can bind to the viral capsid and blocks escape of the virus from the endosome. Human α-defensin 5 increases HIV binding to the cell surface. Human α-defensin 5 also has parasiticidal activity .

Cat. No.	Product Name	Target	Research Area

HY-P991484

ADI-65534	Influenza Virus	Infection
ADI-65534 is a human IgG1 monoclonal antibody (mAb) targeting Envelopment polyprotein, M polyprotein. ADI-65534 can be used in Hantavirus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991483

ADI-65533	Influenza Virus	Infection
ADI-65533 is a human IgG1 monoclonal antibody (mAb) targeting Envelopment polyprotein, M polyprotein. ADI-65533 can be used in Hantavirus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991482

ADI-42898	Influenza Virus	Infection
ADI-42898 is a human IgG1 monoclonal antibody (mAb) targeting Envelopment polyprotein, M polyprotein. ADI-42898 binds to the Gn/Gc complex and blocks the cell entry of seven HCPS- and HFRS-associated hantaviruses. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0222

1-Docosanol 1 Publications Verification Behenyl alcohol	Infection Structural Classification Natural Products other families Classification of Application Fields Source classification Plants Disease Research Fields	HSV
1-Docosanol (Behenyl alcohol) is a saturated fatty alcohol with reported inhibitory activity against lipid-enveloped viruses, including herpes simplex virus (HSV) .

HY-129555

Surfactin 5 Publications Verification	Infection Structural Classification Natural Products Microorganisms Classification of Application Fields Source classification Disease Research Fields	Bacterial HSV Antibiotic
Surfactin is a potent cyclic lipopeptide biosurfactants consists of four isomers (Surfactin A, B, C and D), which mediates flux of mono-and divalent cations, such as calcium, across lipid bilayer membranes. Surfactin can act as an antimicrobial adjuvant with anti-bacterial, anti-fungal, antimycoplasma and hemolytic effects . Surfactin also has antiviral activity against a variety of enveloped viruses .

HY-B0222R

1-Docosanol (Standard)	Structural Classification Natural Products other families Source classification Plants	HSV
1-Docosanol (Standard) is the analytical standard of 1-Docosanol. This product is intended for research and analytical applications. 1-Docosanol (Behenyl alcohol) is a saturated fatty alcohol with reported inhibitory activity against lipid-enveloped viruses, including herpes simplex virus (HSV) .

HY-W019831

Silicon dioxide Silica; Colloidal anhydrous silica	Structural Classification Natural Products Animals Source classification	Endogenous Metabolite
Silicon dioxide (Silica) serves as the core of gold-coated silica nanoparticles, featuring a spherical structure enveloped in a layer of gold nanoparticles on its surface. This composition endows them with distinctive chemical and optical properties, rendering them highly desirable for various applications in medicine, batteries, catalysis, sensors, and spectroscopy. The silica component provides a large surface area, a non-porous nature, outstanding charge transport capabilities, and biocompatibility.

Cat. No.	Product Name	Chemical Structure

HY-14904AS

Umifenovir-d6 hydrochloride
Umifenovir-d₆ (hydrochloride) is the deuterium labeled Umifenovir hydrochloride. Umifenovir hydrochloride is a potent, orally active broad-spectrum antiviral with activity against a number of enveloped and non-enveloped viruses. Umifenovir hydrochloride is used as an anti-influenza virus agent. Umifenovir hydrochloride could effectively inhibit the fusion of virus with host cells . Umifenovir hydrochloride is an efficient inhibitor of SARS-CoV-2 in vitro. Anti-inflammatory activity .

Umifenovir-d6 hydrochloride

Umifenovir-d₆ (hydrochloride) is the deuterium labeled Umifenovir hydrochloride. Umifenovir hydrochloride is a potent, orally active broad-spectrum antiviral with activity against a number of enveloped and non-enveloped viruses. Umifenovir hydrochloride is used as an anti-influenza virus agent. Umifenovir hydrochloride could effectively inhibit the fusion of virus with host cells . Umifenovir hydrochloride is an efficient inhibitor of SARS-CoV-2 in vitro. Anti-inflammatory activity .

HY-14805S

Tecovirimat-d4
Tecovirimat-d₄ (ST-246-d₄) is a deuterium-labelled Tecovirimat (HY-14805). Tecovirimat is an orally bioavailable and selective compound against orthopoxviruses [including vaccinia, monkeypox, camelpox, cowpox, ectromelia (mousepox), smallpox and variola viruses]. Tecovirimat is evaluated against vaccinia, cowpox virus, ectromelia virus with EC₅₀ values of 0.01 μM, 0.48 μM and 0.05 μM, respectively. Tecovirimat targets the orthopoxvirus protein VP37 which is necessary for membrane envelopment of intracellular mature virus particles to form enveloped virus. Tecovirimat exerts antiviral activity on the target of the cowpox virus V061 gene, which is homologous to vaccinia virus F13L, encoding a major envelope protein (p37) required for production of extracellular virus. Tecovirimat could be used in the study for orthopoxvirus-induced diseases .

Tecovirimat-d4

Tecovirimat-d₄ (ST-246-d₄) is a deuterium-labelled Tecovirimat (HY-14805). Tecovirimat is an orally bioavailable and selective compound against orthopoxviruses [including vaccinia, monkeypox, camelpox, cowpox, ectromelia (mousepox), smallpox and variola viruses]. Tecovirimat is evaluated against vaccinia, cowpox virus, ectromelia virus with EC₅₀ values of 0.01 μM, 0.48 μM and 0.05 μM, respectively. Tecovirimat targets the orthopoxvirus protein VP37 which is necessary for membrane envelopment of intracellular mature virus particles to form enveloped virus. Tecovirimat exerts antiviral activity on the target of the cowpox virus V061 gene, which is homologous to vaccinia virus F13L, encoding a major envelope protein (p37) required for production of extracellular virus. Tecovirimat could be used in the study for orthopoxvirus-induced diseases .

HY-B0222S

1-Docosanol-d45
1-Docosanol-d₄₅ is the deuterium labeled 1-Docosanol. 1-Docosanol is a saturated fatty alcohol used traditionally as an emollient, emulsifier, and thickener in cosmetics, and nutritional supplement. 1-Docosanol is an inhibitor of lipid-enveloped viruses including herpes simplex.

HY-169220S

RORγ/DHODH-IN-1
RORγ/DHODH-IN-1 (compound 1404), a deuterium labeled compound, is a dual RORγ and DHODH inhibitor with IC₅₀ values of 9.7 nM and 100 nM, repaectively. RORγ/DHODH-IN-1 blocks the replication of SARS-CoV-2, HCMV, and *non-enveloped* DNA virus (HAdV5)** .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

enveloped

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products